Abstract Argyrophilic grain disease (AgD) is a four-repeat tauopathy that is almost exclusively restricted to allocortical areas. Progressive supranuclear palsy and corticobasal degeneration also show predominant deposition of four-repeat tau filaments, and are associated with the tau H1 haplotype. We investigated a possible association between AgD and the tau H1 haplotype. In AgD, no difference between the prevalence of the tau H1 haplotype or H1/H1 genotype was observed when compared to non-demented control cases. These data suggest that a dysfunction of the tau protein in AgD -in contrast to other fourrepeat tauopathies -may arise irrespective of the genetic background regarding the tau H1 or H2 haplotypes.
Introduction
Argyrophilic grain disease (AgD), first described by Braak and Braak [2, 3] is a sporadic late onset dementia that accounts for approximately 5% of all cases of dementia [5, 13, 17] . Among the oldest-old a recent study suggests that AgD is the second most common cause of degenerative dementia in Japan, after Alzheimer's disease (AD) [12] . Morphologically, AgD is characterized by the presence of neuronal argyrophilic grains (ArGs) in various limbic structures, including the hippocampus, the entorhinal cortex, and the amygdala, and by coiled bodies in oligodendrocytes [2, 3] . Both filamentous lesions consist of the microtubule-associated protein tau in an abnormally hyperphosphorylated state [16] . Recent biochemical studies further revealed that tau filamentous inclusions in AgD consist primarily of tau isoforms with four microtubule-binding repeats (4R-tau) [14, 12, 19] .
The predominant deposition of 4R-tau is also a feature of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) [7] , and both tauopathies have been shown to be associated with the tau H1 haplotype [1, 6] . A recent study also suggests a trend towards an increased tau H1 haplotype in AgD. However, no statistically significant difference was found between AgD and non-tauopathy controls [14] . Based on these findings, we investigated the tau H1 haplotype in AgD, and wanted to know whether the 4R tauopathies share a common pathogenic mechanism causing dysfunction of the tau protein. Tau haplotypes H1 and H2 were analyzed in a sample of 79 subjects with neuropathologically confirmed AgD according to published criteria [5, 13, 17] , and in a sample of 148 nondemented control subjects without ArGs.
Material and methods
AgD cases (n=79) diagnosed at the Department of Neuropathology, Basel University, Switzerland were included in the present study. There were 33 males, 46 females, with a median age of 85.9 years (66-96 years). Standard neuropathological examination was performed including the Gallyas silver technique, and immunohistochemistry using antibodies against tau (AT8; 1:1,000; Innogenetics, Gent, Belgium), β-amyloid (1:50; Dako, Glostrup, Denmark), α-synuclein (1:2,000; Zymed, San Francisco, CA) and αB-crystallin (1:1,000; Novocastra, Newcastle, UK). As controls, 148 nondemented subjects were randomly selected from the Basel InterDisciplinary study on Aging (IDA), Switzerland [10] . For molecular analysis, paraffin-embedded tissue samples and/or blood samples from the AgD cases and blood samples from the controls were used.
Genomic DNA was extracted from tissue samples using DNeasy tissue kits from Qiagen (Hilden, Germany), and from nucleated André R. Miserez · Florence Clavaguera · Andreas U. Monsch · Alphonse Probst · Markus Tolnay Argyrophilic grain disease: molecular genetic difference to other four-repeat tauopathies blood cells by the salting out method with modifications as described [8] , or using the QIAmp DNA blood kit. Taq DNA polymerase and deoxyribonucleotides were from Applied Biosystems (Norwalk, CT). Oligonucleotides were synthesized by Microsynth Inc. (Balgach, Switzerland); Spreadex EL 300 Wide-Mini S-100 gels were from Elchrom Inc. (Cham, Switzerland). To characterize the 238-bp deletion in intron 9, which corresponds to the H2 haplotype of the tau gene, the part of intron 9 containing the 238-bp deletion was amplified using primers as previously described [1] . The amplicon was separated on a 2% agarose gel, dissolved, purified, and subjected to dideoxy sequencing. The presence of the intronic deletion was determined by allele-specific PCR. To investigate the presence of the deletion in each sample, the allele-specific antisense primer tau-del9.asR, 5´-ATGGGTCTCCCACGACTGCATT-3( primer B), complimentary to parts of the intron sequence of the deletion, was designed. Using all three primers [tau-del9F (A), taudel19.asR (B), and tau-del19.R (C)] in the same reaction combined (multiplex PCR) or pairs of primers (A/B and A/C), the presence of the deletion could be determined for both alleles of the individual investigated. Using the primer combination A/C, a fragment of 484 bp was obtained if the deletion was absent and a fragment of 246 bp if the intronic sequence was deleted. However, as the probability of amplifying a fragment of 484 bp is theoretically lower than the probability of amplifying a fragment of 246 bp, we also used the primer combination A/B. This PCR results in a fragment of 187 bp if the intronic fragment is not deleted (Fig. 1A) . For group comparison, the Chi-square statistic was used.
Results
Histologically, all AgD cases were characterized by the presence of abundant ArGs in limbic areas, including sector CA1 of the hippocampus, the entorhinal cortex and the amygdala. Coiled bodies were mainly found in the white matter underneath cortical regions rich in ArGs. AT8 revealed various numbers of pretangle neurons in all AgD cases as previously described [16] . In all cases, αB-crystallin-stained ballooned neurons were predominantly found in the amygdala, corroborating earlier results [15] . Associated neurofibrillary tangles of the AD type were found in a density and distribution corresponding to early transento- sions (e.g., small lacunar infarcts and/or cribriform state of the basal ganglia) were found in 19 (24.1%) cases. All AgD cases were devoid of concomitant PSP and CBD pathology. The neuropathological findings of 24 cases have been reported in earlier studies [17] . According to the clinical records, 61 (77.2%) subjects with ArGs were reported to be demented. Figure 1B presents the sequence containing the 238-bp deletion as well as the localization of the deletion itself. Molecular analysis revealed the following tau genotype frequencies for the AgD cases: genotype H1/H1 46 patients (58.2%), genotype H1/H2 30 patients (38.0%), and genotype H2/H2 3 patients (3.8%). The tau genotype frequencies of the non-demented control group did not differ significantly from that of the AgD cases (P=0.672). Hence, among the AgD cases, the H1 allele was found in 77.2% and the H2 allele in 22.8%, respectively. These values did not differ significantly from those obtained in the non-demented control group (P=0.964) ( Table 1) .
Discussion
PSP and CBD are sporadic extrapyramidal syndromes characterized by predominant 4R tau deposition, and both have been shown to be associated with the tau H1 haplotype [1, 6] . The sporadic late-onset dementia AgD has recently been recognized as a 4R tauopathy [14, 18, 19] . Preliminary data based on a limited number of cases opened the possibility that the tau H1 haplotype might also be overrepresented in AgD [14] . To test the hypothesis whether the association of the tau H1 haplotype represents a common feature among 4R tauopathies, we analyzed the tau haplotype in a cohort of 79 autopsy-confirmed AgD cases. In contrast to PSP and CBD [1, 6] , no difference was found between the prevalence of the tau H1 haplotype or the H1/H1 genotype in subjects with AgD when compared to non-demented control cases.
The tau haplotype frequencies may vary when they are studied in different populations. The tau H1/H1 genotype is known to be very low in Norway (50%), while it is very high in Japan (>95%). In our study, both the AgD and the control cohorts are derived from the same urban-suburban area in a northwestern region of Switzerland. In the control cohort the frequencies of the tau H1 haplotype (77.0%) and H1/H1 genotype (60.1%) are quite comparable with values reported in different US-and UK-based populations [1, 6, 9, 14] .
The present study suggests that there is no obligatory association between the tau H1 haplotype and the 4R tauopathies. Thus, the presence of the tau H1 haplotype seems not to be a prerequisite for the type of filamentous tau protein deposited in 4R tauopathies. No association between the tau H1 or H2 haplotype has been found in Pick's disease [9, 11] , a tauopathy characterized by the predominant deposition of 3R tau filaments.
PSP, CBD and AgD share pathological and biochemical similarities with regard to an abnormal tau deposition. In all these disorders, predominantly 4R tau filamentous inclusions are found in neurons, astrocytes and oligodendrocytes. A recent study further demonstrates a high prevalence of ArGs in PSP and CBD cases [14] . In contrast, a high prevalence of PSP and CBD cases has not been observed in AgD cases, even in large cohorts of cases [5, 17] . Other differences, however, may confirm the separation of PSP and CBD from AgD as distinct clinicopathological entities. Clinically, PSP patients present with postural instability, supranuclear vertical gaze palsy, parkinsonism, pseudobulbar palsy and subcortical dementia. CBD patients also exhibit motor symptoms, parkinsonism and eye movement abnormalities, and dementia has been reported as their presenting syndrome in the majority of CBD patients. In contrast, although the clinical characteristics of AgD remain to be fully established, motor symptoms and parkinsonism are not characteristic features of AgD. Recent studies rather suggest that AgD patients present with dementia, and that personality changes and emotional imbalances may precede memory failure [17] . The different clinical presentation among 4R tauopathies is a function of the anatomical distribution of their pathology. Thus, PSP and CBD are characterized by a widespread tau pathology in various cortical and subcortical structures, including brain stem, while tau filamentous lesions in AgD are almost exclusively restricted to allocortical areas. Whether the tau haplotypes may affect the different topology of neurodegeneration among 4R tauopathies remains to be elucidated.
In conclusion, the present study further establishes AgD as a rather distinct pathological entity within the heterogeneous group of tauopathies. Hence, the clinicopathological differences between the 4R tauopathies PSP and CBD on one hand and AgD on the other might be explained by genetic or non-genetic differences that are involved in the development of the tau protein dysfunction. 
